Literature DB >> 33104438

Targeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations.

Timothy F Burns1, Hossein Borghaei2, Suresh S Ramalingam3, Tony S Mok4, Solange Peters5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33104438      PMCID： PMC7723684          DOI： 10.1200/JCO.20.00744

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  107 in total

1.  K-Ras(G12D)-selective inhibitory peptides generated by random peptide T7 phage display technology.

Authors:  Kotaro Sakamoto; Yusuke Kamada; Tomoya Sameshima; Masahiro Yaguchi; Ayumu Niida; Shigekazu Sasaki; Masanori Miwa; Shoichi Ohkubo; Jun-Ichi Sakamoto; Masahiro Kamaura; Nobuo Cho; Akiyoshi Tani
Journal:  Biochem Biophys Res Commun       Date:  2017-01-30       Impact factor: 3.575

2.  Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.

Authors:  Antonio Calles; Xiaoyun Liao; Lynette M Sholl; Scott J Rodig; Gordon J Freeman; Mohit Butaney; Christine Lydon; Suzanne E Dahlberg; F Stephen Hodi; Geoffrey R Oxnard; David M Jackman; Pasi A Jänne
Journal:  J Thorac Oncol       Date:  2015-12       Impact factor: 15.609

3.  Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition.

Authors:  Meagan B Ryan; Ferran Fece de la Cruz; Sarah Phat; David T Myers; Edmond Wong; Heather A Shahzade; Catriona B Hong; Ryan B Corcoran
Journal:  Clin Cancer Res       Date:  2019-11-27       Impact factor: 12.531

4.  Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).

Authors:  Arnaud Jeanson; Pascale Tomasini; Maxime Souquet-Bressand; Nicolas Brandone; Mohamed Boucekine; Mathieu Grangeon; Solène Chaleat; Natalyia Khobta; Julie Milia; Laurent Mhanna; Laurent Greillier; Julie Biemar; Isabelle Nanni; L'houcine Ouafik; Stéphane Garcia; Julien Mazières; Fabrice Barlesi; Céline Mascaux
Journal:  J Thorac Oncol       Date:  2019-02-06       Impact factor: 15.609

5.  Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.

Authors:  Zhong-Yi Dong; Wen-Zhao Zhong; Xu-Chao Zhang; Jian Su; Zhi Xie; Si-Yang Liu; Hai-Yan Tu; Hua-Jun Chen; Yue-Li Sun; Qing Zhou; Jin-Ji Yang; Xue-Ning Yang; Jia-Xin Lin; Hong-Hong Yan; Hao-Ran Zhai; Li-Xu Yan; Ri-Qiang Liao; Si-Pei Wu; Yi-Long Wu
Journal:  Clin Cancer Res       Date:  2016-12-30       Impact factor: 12.531

6.  The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy.

Authors:  Martin Svaton; Ondrej Fiala; Milos Pesek; Zbynek Bortlicek; Marek Minarik; Lucie Benesova; Ondrej Topolcan
Journal:  Anticancer Res       Date:  2016-03       Impact factor: 2.480

7.  The status of KRAS mutations in patients with non-small cell lung cancers from mainland China.

Authors:  Mei Li; Lina Liu; Zhimin Liu; Shichang Yue; Luming Zhou; Qiuping Zhang; Shihua Cheng; Rachel W Li; Paul N Smith; Shen Lu
Journal:  Oncol Rep       Date:  2009-11       Impact factor: 3.906

8.  Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer.

Authors:  Ke-Jing Tang; Jerfiz D Constanzo; Niranjan Venkateswaran; Margherita Melegari; Mariya Ilcheva; Julio C Morales; Ferdinandos Skoulidis; John V Heymach; David A Boothman; Pier Paolo Scaglioni
Journal:  Clin Cancer Res       Date:  2016-05-24       Impact factor: 12.531

Review 9.  New perspectives for targeting RAF kinase in human cancer.

Authors:  Zoi Karoulia; Evripidis Gavathiotis; Poulikos I Poulikakos
Journal:  Nat Rev Cancer       Date:  2017-10-06       Impact factor: 60.716

10.  The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.

Authors:  Jill Hallin; Lars D Engstrom; Lauren Hargis; Andrew Calinisan; Ruth Aranda; David M Briere; Niranjan Sudhakar; Vickie Bowcut; Brian R Baer; Joshua A Ballard; Michael R Burkard; Jay B Fell; John P Fischer; Guy P Vigers; Yaohua Xue; Sole Gatto; Julio Fernandez-Banet; Adam Pavlicek; Karen Velastagui; Richard C Chao; Jeremy Barton; Mariaelena Pierobon; Elisa Baldelli; Emanuel F Patricoin; Douglas P Cassidy; Matthew A Marx; Igor I Rybkin; Melissa L Johnson; Sai-Hong Ignatius Ou; Piro Lito; Kyriakos P Papadopoulos; Pasi A Jänne; Peter Olson; James G Christensen
Journal:  Cancer Discov       Date:  2019-10-28       Impact factor: 38.272
View more
  6 in total

Review 1.  The treatment of advanced non-small cell lung cancer harboring KRAS mutation: a new class of drugs for an old target-a narrative review.

Authors:  Alessia Spagnuolo; Paolo Maione; Cesare Gridelli
Journal:  Transl Lung Cancer Res       Date:  2022-06

2.  FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC.

Authors:  Erica C Nakajima; Nicole Drezner; Xiaoxue Li; Pallavi S Mishra-Kalyani; Yajun Liu; Hong Zhao; Youwei Bi; Jiang Liu; Atiqur Rahman; Emily Wearne; Idara Ojofeitimi; Lauren Tesh Hotaki; Dianne Spillman; Richard Pazdur; Julia A Beaver; Harpreet Singh
Journal:  Clin Cancer Res       Date:  2022-04-14       Impact factor: 13.801

3.  KRAS Mutations Impact Clinical Outcome in Metastatic Non-Small Cell Lung Cancer.

Authors:  Ella A Eklund; Clotilde Wiel; Henrik Fagman; Levent M Akyürek; Sukanya Raghavan; Jan Nyman; Andreas Hallqvist; Volkan I Sayin
Journal:  Cancers (Basel)       Date:  2022-04-20       Impact factor: 6.575

Review 4.  Targeting KRAS in Non-Small Cell Lung Cancer.

Authors:  Elena Corral de la Fuente; Maria Eugenia Olmedo Garcia; Ana Gomez Rueda; Yolanda Lage; Pilar Garrido
Journal:  Front Oncol       Date:  2022-01-10       Impact factor: 6.244

Review 5.  Therapeutic Potential of Intrabodies for Cancer Immunotherapy: Current Status and Future Directions.

Authors:  Thomas Böldicke
Journal:  Antibodies (Basel)       Date:  2022-07-18

6.  Molecular Targets in Lung Cancer: Study of the Evolution of Biomarkers Associated with Treatment with Tyrosine Kinase Inhibitors-Has NF1 Tumor Suppressor a Key Role in Acquired Resistance?

Authors:  Begoña O Alen; Lara S Estévez-Pérez; María Teresa Hermida-Romero; Ana Reguera-Arias; Rosario García-Campelo; Mercedes de la Torre-Bravos; Ángel Concha
Journal:  Cancers (Basel)       Date:  2022-07-07       Impact factor: 6.575
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.